Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
04 10월 2023 - 8:00PM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that Dr. Shankar Musunuri, Chairman,
Chief Executive Officer and Co-Founder of Ocugen will present at
the 2023 Cell & Gene Meeting on the Mesa being held October
10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.
Dr. Musunuri will provide an overview of
Ocugen’s clinical development programs, including the business
strategy across its unique gene and cell therapy platforms,
anticipated milestones, and more detail about the Company’s recent
positive Phase 1/2 OCU400 data results.
Details of the presentation are as
follows:
Event: |
2023 Cell & Gene Meeting
on the Mesa |
Date &
Time: |
October 11, 2023 at 5:15 PM,
PDT |
Location: |
Park Hyatt Aviara Resort,
Carlsbad, CA, Aseptic Technologies Ballroom |
“The Cell & Gene Meeting on the Mesa
convenes leading industry professionals confronting major
scientific, logistic, policy, and economic questions in cell and
gene therapy,” said Dr. Musunuri. “I am pleased to join this
impressive group and share the latest gene therapy news from
Ocugen—compelling positive results from our Phase 1/2 trial of
OCU400 for the treatment of retinitis pigmentosa (RP) and Leber
congenital amaurosis (LCA)—as well as our progress toward
initiating the Phase 3 trial for the Company’s novel cell therapy
product candidate for cartilage repair in the second half of
2024.”
Virtual attendance is available, which includes
a livestream of Ocugen’s presentation and on-demand viewing of all
conference sessions. Please visit https://meetingonthemesa.com for
full information including registration.
About Ocugen, Inc. Ocugen,
Inc. is a biotechnology company focused on discovering, developing,
and commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patients’ lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Forward-Looking
Statements This press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should,” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks, and uncertainties that may cause actual
events or results to differ materially from our current
expectations. These and other risks and uncertainties are more
fully described in our periodic filings with the Securities and
Exchange Commission (SEC), including the risk factors described in
the section entitled “Risk Factors” in the quarterly and annual
reports that we file with the SEC. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. Except as required by law, we assume no
obligation to update forward-looking statements contained in this
press release whether as a result of new information, future
events, or otherwise, after the date of this press
release.
Contact: Tiffany
Hamilton Head of
Communications Tiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ocugen (NASDAQ:OCGN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024